Inhibitor Therapeutics (INTI) Short Interest Ratio & Short Volume

Short interest is the volume of Inhibitor Therapeutics shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 11,300 shares of INTI short. Learn More on Inhibitor Therapeutics' current short interest.

Inhibitor Therapeutics saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 11,300 shares, an increase of ∞ from the previous total of 0 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Inhibitor Therapeutics: Cue Biopharma, Inc. (3.66%), Precision BioSciences, Inc. (5.77%), Iterum Therapeutics plc (11.53%), Shattuck Labs, Inc. (5.31%), Provectus Biopharmaceuticals, Inc. (0.02%), Protara Therapeutics, Inc. (13.28%), Atlantic Coastal Acquisition Corp. II (0.49%), DBV Technologies S.A. (1.41%), CalciMedica, Inc. (1.36%), Immix Biopharma, Inc. (2.66%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

Short selling INTI is an investing strategy that aims to generate trading profit from Inhibitor Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Inhibitor Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of INTI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INTI, twice per month. The most recent reporting period available is October, 31 2024.